ERBB2 and cancer: Since resistance towards HER2 targeting can be expected [4, 5], and since the major challenge in HER2 positive cancer is its highly invasive nature, an alternative approach would be to develop therapies that target the invasion-promoting functions of HER2/ErbB2.